Zhonghua Yan Ke Za Zhi. 2024 Aug 11;60(8):648-657. doi: 10.3760/cma.j.cn112142-20240124-00045.
With the increasing incidence of myopia year by year and the continuous progress of various treatment techniques, laser corneal refractive surgery has become one of the important ways to correct refractive errors. The rational drug use in the perioperative period is important for the success of surgery and reduction of complications. In 2019, based on the development of laser corneal refractive surgery in China, experts from the Refractive Surgery Experts Group of Ocular Microcirculation Branch of Chinese Society of Microcirculation and the Ophthalmology Branch in the Chinese Medical Association formed the "Chinese Expert Consensus on the Perioperative Medication in Laser Corneal Refractive Surgery (2019)". To further promote the expansion of new clinical technologies and surgical methods, and to improve surgical efficacy, the Refractive Surgery Experts Group of Ocular Microcirculation Branch of Chinese Society of Microcirculation, according to the latest domestic and foreign research results, has recently updated the consensus after a collective discussion.
随着近视发病率逐年上升以及各种治疗技术的不断进步，准分子激光角膜屈光手术已成为矫正屈光不正的重要手段之一。围手术期合理用药对于手术成功及减少并发症至关重要。2019年，基于我国准分子激光角膜屈光手术的发展情况，中国微循环学会眼微循环专业委员会屈光手术学组与中华医学会眼科学分会专家共同制定了《准分子激光角膜屈光手术围手术期用药专家共识（2019年）》。为进一步推动新临床技术及手术方式的拓展，提高手术疗效，中国微循环学会眼微循环专业委员会屈光手术学组根据国内外最新研究成果，经集体讨论后对该共识进行了更新。
